The increased release of irisin under such conditions could reflect a response to deterioration or a compensatory increase to overcome an underlying insulin resistance, nonalcoholic fatty liver disease or subclinical atherosclerosis [29]. Here, FNDC5 is linked to metabolic dysfunction-associated steatotic liver disease.